<DOC>
	<DOC>NCT00889603</DOC>
	<brief_summary>The Aricept® Evess study is a prospective, non-comparative, non-interventional study on use of Aricept® Evess in the treatment of out-patients with AD and Vascular Dementia. The 24 week length of the study aims to collect data from a large number of patients (n= 400) on the safety and efficacy at the usual dosage of the product providing an overview of Aricept® Evess profile.</brief_summary>
	<brief_title>Non-Interventional Study With Aricept® Evess</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia, Vascular</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Outpatients (male / female), older than 50 years. Patients with clinical symptoms of mild and moderate AD and Vascular Dementia. MMSE score between 12 24. Patients with a known hypersensitivity to donepezil clorhydrat, piperidine derivatives or any of the excipients of Aricept® Evess. Patients with severe impaired hepatic function. Patients with preexisting gastrointestinal ulcer disease. Patients with the history of bronchial asthma or chronic obstructive lung disease. Patients with the history of serious atrioventricular conduction disturbances.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Aricept® Evess</keyword>
	<keyword>non-interventional study</keyword>
	<keyword>Alzheimer's Disease</keyword>
	<keyword>Vascular Dementia</keyword>
	<keyword>efficacy</keyword>
	<keyword>tolerability</keyword>
	<keyword>safety.</keyword>
</DOC>